1.  Evans WE, McLeod HL. (2003). Pharmacogenomics- Drug Disposition, Drug Targets, and Side Effects. N Engl J Med 348(6): 538-49

2.  Samer CF, Lorenzini KI, Rollason V, Daali Y, and Desmeules JA. (2013). Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther. 17(3): 165-184

3.  Zaretzki J et al. (2011). RS-predictor: a new tool for predicting sites of cytochrome p450-mediated metabolism applied to CYP 3A4. J Chem Inf Model. 51(7): 1667-89

4.  Guengerich FP. (2006). Cytochrome 450s and other enzymes in drug metabolism and toxicity. AAPS J. 8(1): E101-E111.

5.  Kudzma EC, Carey ET. (2009). Pharmacogenomics: personalized drug therapy. Am J Nurs. 109(10): 50-7; quiz 58.

6.  Rochon PA. (2014). Drug Prescribing for Older Adults. UpToDate. Available from:

7.  Medication Safety Basics. Centers for Disease Control and Prevention, Medication Safety Program. Updated 8/14/2012. Available from:

8.  Branham A et al. (2010). Retrospective Analysis of Medication Adherence and Cost Following Medication Therapy Management. Innovations. Available from: cop_article_254656.pdf

9.  Verbeurgt P. (2014). How common are drug and gene interactions? Prevalence in a Sample of 1143 Patients with CYP2C9, CYP2C19, and CYP2D6 Genotyping. Pharmacogenomics. 15(5): 655-665

10.  DemlerTL (2013). Psychiatric Drug-Drug Interactions. US Pharmacist. 37(11): HS-16-HS-19. Available from: viewarticle/775394_3

11.  Fagerness J et al. (2014). Pharmacogenetic-Guided Psychiatric Intervention Associated with Increased Adherence and Cost Savings. Am J Manag Care. j20(5): e146-e156

12.  Epstein, RS et al. (2010). Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). Journal of the American College of Cardiology, 55(25), 2804–12. doi:10.1016/j.jacc.2010.03.009

13.  Herman B. (2013) 11 Statistics on Average Hospital Costs Per stay. Available from: statistics-on-average-hospital-costs-per-stay.html

14.  Relling MV, Klein TE. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Nature. 89(3) 464-7.

Corporate Headquarters: ArcticDx Inc.

MaRs Centre, 661 University Ave.  Suite 455

Toronto, Ontario  M5G 1M1  Canada


T: 1 (866) 964-5182                        F: 1 (866) 964-5184


Email: or

© Arctic Group Of Companies. All Rights Reserved.

Privacy Policy. Terms and Conditions